Last reviewed · How we verify
mifepristone and misopristol
Mifepristone blocks progesterone receptors to halt pregnancy, while misoprostol induces uterine contractions to expel the pregnancy.
Mifepristone blocks progesterone receptors to halt pregnancy, while misoprostol induces uterine contractions to expel the pregnancy. Used for Medical abortion (termination of intrauterine pregnancy up to 10 weeks gestation).
At a glance
| Generic name | mifepristone and misopristol |
|---|---|
| Sponsor | Hadassah Medical Organization |
| Drug class | Progesterone receptor antagonist + prostaglandin analog combination |
| Target | Progesterone receptor (PR) and prostaglandin E1 receptor (EP receptor) |
| Modality | Small molecule |
| Therapeutic area | Reproductive Health / Obstetrics |
| Phase | FDA-approved |
Mechanism of action
Mifepristone is a selective progesterone receptor antagonist that prevents progesterone from maintaining the uterine lining and pregnancy. Misoprostol is a prostaglandin analog that stimulates uterine contractions to facilitate expulsion of pregnancy tissue. Together, they comprise a medical abortion regimen.
Approved indications
- Medical abortion (termination of intrauterine pregnancy up to 10 weeks gestation)
Common side effects
- Vaginal bleeding
- Abdominal pain/cramping
- Nausea
- Vomiting
- Diarrhea
- Headache
- Dizziness
- Fever
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mifepristone and misopristol CI brief — competitive landscape report
- mifepristone and misopristol updates RSS · CI watch RSS
- Hadassah Medical Organization portfolio CI